NCT05387928View on ClinicalTrials.gov

A Study of KL340399 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 7, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

KL340399 injection

KL340399 injection is a STING-activating. The strength of KL340399 is 0.2 mg/vial，0.2 mg/vial.

Trial Locations (1)

100142

RECRUITING

Beijing Cancer Hospital, Beijing

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY